Table 2. Tyrosine kinase inhibitors (TKIs) and ABCC10 modulators.

Compound	Concentrations	Effect on ABCC10 substrate drug	Effect on accumulation of [3H]-paclitaxel	Effect on efflux of [3H]-paclitaxel	Effect on ABCC10 protein expression
Cepharanthine[24]	2 µmol/L	+	↑	↓	↔
Imatinib[28]	1, 2.5, 5 µmol/L	+	↑	↓	↔
Nilotinib[28]	1, 2.5, 5 µmol/L	+	↑	↓	↔
Lapatinib[33]	0.625, 1.25, 2.5 µmol/L	+	↑	↓	↔
Erlotinib[33]	0.625, 1.25, 2.5 µmol/L	+	↑	↓	↔
Sorafenib[19]	5 µmol/L	+	N/A	N/A	N/A
Sildenafil[41]	1.25, 2.5, 5 µmol/L	+	↑	↓	↔
Vardenafil[41]	1.25, 2.5, 5 µmol/L	+	↑	↓	↔
Tariquidar[61]	0.1, 0.3 µmol/L	+	↑	↓	↓ (>24 h treatment)
Tandutinib[47]	5, 10 µmol/L	+	↑	↓	↔

(+): this compound shows reversal activity for the ABCC10 transporter; (-): this compound shows no reversal activity for the ABCC10 transporter; (↑): increase or up-regulate; (↓): decrease or down-regulate; (↔): no significant alterations; (N/A): not applicable.